痙攣治療市場規模、佔有率、成長分析（按類型、藥物類別、最終用戶、適應症、給藥途徑和地區）- 產業預測（2025 年至 2032 年）

2023 年全球痙攣治療市場規模為 15 億美元，預計將從 2024 年的 15.7 億美元成長到 2032 年的 23.1 億美元，預測期內（2025-2032 年）的複合年成長率為 4.9%。

全球痙攣治療市場正在經歷顯著成長，這得益於多發性硬化症和腦性麻痹等神經系統疾病盛行率的上升。人們對可用治療方案的認知不斷提高，以及治療方法的進步，包括藥物和非藥物干預，正在增強市場活力。此外，對個人化醫療日益成長的需求正在影響針對個別患者需求的創新治療方案的發展。醫療保健提供者和製藥公司之間的合作也刺激了研發，從而引入了更有效的治療方法。此外，政府旨在改善醫療保健基礎設施和治療機會的舉措預計將推動市場擴張，使其成為更廣泛的醫療保健領域中一個有前景的領域。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 定價分析
• 案例研究

痙攣治療市場規模（按類型及複合年成長率）（2025-2032）

• 市場概覽
• 藥物治療
• 物理治療
• 手術治療

痙攣治療市場規模（按藥物類別和複合年成長率） (2025-2032)

• 市場概覽
• GABA促效劑
• α-2腎上腺素促效劑
• 肉毒桿菌毒素
• 其他藥物類別

痙攣治療市場規模（按最終用戶和複合年成長率） (2025-2032)

• 市場概覽
• 醫院
• 門診手術中心
• 居家照護環境
• 專科診所
• 診斷中心

痙攣治療市場規模（按適應症和複合年成長率） (2025-2032)

• 市場概覽
• 腦性麻痹
• 多發性硬化症
• 創傷性腦損傷
• 其他

痙攣治療市場規模（依給藥途徑及複合年成長率） (2025-2032)

• 市場概覽
• 口服
• 腸外

痙攣治療市場規模及複合年成長率：按地區（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益同比對比（2022-2024 年）

主要企業簡介

• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline plc
• Medtronic
• Pfizer Inc
• Ipsen Pharma
• UCB Pharma Ltd
• INMED PHARMACEUTICALS INC
• Orient Pharma
• Taj Pharmaceuticals Limited
• Johnson & Johnson Services, Inc.
• MediciNova, Inc.
• Sun Pharmaceutical Industries Ltd
• Novartis AG
• Teva Pharmaceutical Industries Ltd
• Merz Pharma
• Acorda Therapeutics, Inc.

結論和建議

Global Spasticity Treatment Market size was valued at USD 1.5 billion in 2023 and is poised to grow from USD 1.57 billion in 2024 to USD 2.31 billion by 2032, growing at a CAGR of 4.9% during the forecast period (2025-2032).

The global spasticity treatment market is witnessing significant growth, driven by the rising prevalence of neurological disorders such as multiple sclerosis and cerebral palsy. Increasing awareness regarding the available treatment options and advancements in therapies, including both pharmacological and non-pharmacological interventions, are enhancing market dynamics. Additionally, the growing demand for personalized medicine is influencing the development of innovative treatment solutions tailored to individual patient needs. The collaboration between healthcare providers and pharmaceutical companies is also fostering research and development, leading to the introduction of more effective therapies. Furthermore, government initiatives aimed at improving healthcare infrastructure and access to treatment are expected to bolster market expansion, making it a promising segment within the broader healthcare landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Spasticity Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Spasticity Treatment Market Segments Analysis

Global Spasticity Treatment Market is segmented by Type, Drug Class, End-user, Indication, Route Of Administration and region. Based on Type, the market is segmented into Drug therapy, Physical therapy and Surgical treatment. Based on Drug Class, the market is segmented into GABA Agonist, Alpha2-adrenergic Agonists, Botulinum Toxins and Other Drug Class. Based on End-user, the market is segmented into Hospitals, Ambulatory surgical centers, Home care settings, Specialty clinics and Diagnostic centers. Based on Indication, the market is segmented into Cerebral palsy, Multiple sclerosis, Traumatic brain injury and Others. Based on Route Of Administration, the market is segmented into Oral and Parenteral. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Spasticity Treatment Market

One of the primary factors propelling the spasticity treatment market is the rising incidence of neurological disorders, including conditions such as cerebral palsy, multiple sclerosis, and spasticity resulting from strokes. As these disorders become increasingly common worldwide, there is an escalating need for effective treatment options. This demand encompasses a range of therapies, including oral medications, physical rehabilitation, and the use of botulinum toxins, which are essential in managing symptoms. Consequently, this heightened focus on effective intervention strategies is significantly driving the expansion and development of the spasticity treatment market.

Restraints in the Global Spasticity Treatment Market

The Global Spasticity Treatment market faces significant challenges due to the high costs associated with various treatment options, particularly advanced therapies such as botulinum toxin injections and physical rehabilitation. Patients, particularly those in low-income regions, often struggle to access these essential treatments. Financial barriers, including limitations imposed by insurance coverage and substantial out-of-pocket expenses, further hinder patient access. These economic constraints not only impact individual patients but also contribute to a stagnation in the overall growth of the industry, as many potential users are unable to afford the necessary care for managing spasticity effectively.

Market Trends of the Global Spasticity Treatment Market

The Global Spasticity Treatment market is witnessing a significant shift towards the implementation of minimally invasive procedures, reflecting a broader trend in medical practices for improved patient outcomes. The adoption of intrathecal medication infusion devices and botulinum toxin injections has gained prominence among healthcare providers managing localized spasticity, as these techniques deliver effective temporary relief with reduced pain and quicker recovery times. This growing preference for less invasive options is not only enhancing patient comfort but also driving market growth, as advancements in technology and increasing awareness among healthcare professionals contribute to the rising demand for innovative spasticity management solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Pricing Analysis
• Case Studies

Global Spasticity Treatment Market Size by Type & CAGR (2025-2032)

• Market Overview
• Drug therapy
• Physical therapy
• Surgical treatment

Global Spasticity Treatment Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• GABA Agonist
• Alpha2-adrenergic Agonists
• Botulinum Toxins
• Other Drug Class

Global Spasticity Treatment Market Size by End-user & CAGR (2025-2032)

• Market Overview
• Hospitals
• Ambulatory surgical centers
• Home care settings
• Specialty clinics
• Diagnostic centers

Global Spasticity Treatment Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Cerebral palsy
• Multiple sclerosis
• Traumatic brain injury
• Others

Global Spasticity Treatment Market Size by Route Of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral

Global Spasticity Treatment Market Size & CAGR (2025-2032)

• North America (Type, Drug Class, End-user, Indication, Route Of Administration)
  • US
  • Canada
• Europe (Type, Drug Class, End-user, Indication, Route Of Administration)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Drug Class, End-user, Indication, Route Of Administration)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Drug Class, End-user, Indication, Route Of Administration)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Drug Class, End-user, Indication, Route Of Administration)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB Pharma Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• INMED PHARMACEUTICALS INC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orient Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Taj Pharmaceuticals Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MediciNova, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merz Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acorda Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations